News & publications
The latest from Strata Oncology
Results for “”
Press releases
Strata Oncology Announces Positive Results from Independent Evaluation of First of Its Kind Predictive Antibody Drug Conjugate (ADC) Biomarker
Strata Oncology Announces Presentations on Proprietary Multivariate Biomarkers at North America Conference on Lung Cancer and San Antonio Breast Cancer Symposium
Strata Oncology Recognized as “Diagnostics Innovation Of The Year” by BioTech Breakthrough Awards
In the news
Manuscripts
Cancer Research Communications
Validation of Immunotherapy Response Score as predictive of pan-solid tumor anti-PD-1/PD-L1 benefit
Communications Medicine
Development and validation of an integrative pan-solid tumor predictor of PD-1/PD-L1 blockade benefit
npj Precision Oncology
Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial
Case reports
Abstracts
Antibody Drug Conjugates Treatment Response Score (ADC TRS) for predicting ADC treatment response
IASLC23
Immunotherapy Response Score (IRS) Predicts Pembrolizumab Clinical Benefit in Patients with NSCLC in TPS≥50%
ASCO 2023
Evaluation of Immunotherapy Response Score (IRS) for Predicting Pembrolizumab (pembro) Clinical Benefit in Patients (pts) with Advanced Solid Tumors
Poster
IASLC23
Immunotherapy Response Score (IRS) Predicts Pembrolizumab Clinical Benefit in Patients with NSCLC in TPS≥50%
AACR 2023
Validation of an Integrative Pan-solid Tumor Predictor of Pembrolizumab Monotherapy Benefit
AACR 2023
Strata PATH™: A Multicohort, Non-randomized, Open-label Phase 2 Trial to Explore Efficacy and Safety of FDA-Approved Cancer Therapies in Novel Biomarker-guided Patient Population
We couldn't find any results for “”. Please try another search.